Changing the course for lung cancer treatment
Harnessing antisense oligonucleotides for a first-in-class therapy
Treating an unmet need at RNA level
A promising breakthrough for clinical oncology
The TAONas-LUAD project partners work on a new technology to treat
lung adenocarcinomas, the most common type of lung cancer. Our
goal is to develop a widely applicable therapy based on the use of antisense oligonucleotides.
From the lab to the benefit of patients
Our proprietary technology is headed towards clinical trials
Our aim is to develop a therapy that has real impact for lung cancer patients. We will fund a spin-off company AON-THERAPEUTICS to guarantee that our research translates into a clinically approved, highly effective treatment.
Experts in translational cancer research
A team of top-class institutions from across Europe
Our consortium brings together multidisciplinary know-how from research and technology transfer.
